` ACXP (Acurx Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

ACXP
vs
S&P 500

Over the past 12 months, ACXP has underperformed S&P 500, delivering a return of -81% compared to the S&P 500's +13% growth.

Stocks Performance
ACXP vs S&P 500

Loading
ACXP
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
ACXP vs S&P 500

Loading
ACXP
S&P 500
Difference
www.alphaspread.com

Performance By Year
ACXP vs S&P 500

Loading
ACXP
S&P 500
Add Stock

Competitors Performance
Acurx Pharmaceuticals Inc vs Peers

S&P 500
ACXP
ABBV
AMGN
GILD
VRTX
Add Stock

Acurx Pharmaceuticals Inc
Glance View

Market Cap
10.1m USD
Industry
Biotechnology

Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Staten Island, New York and currently employs 3 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in developing a class of antibiotics for infections caused by bacteria listed as pathogens by the World Health Organization (WHO), the United States Centers for Disease Control and Prevention, and the United States Food and Drug Administration (FDA). The firm develops antibiotic candidates that block the deoxyribonucleic acid (DNA) polymerase IIIC enzyme (Pol IIIC). Pol IIIC is the primary catalyst for DNA replication in Gram-positive bacterial cells. Its research and development pipeline include clinical-stage and early stage antibiotic candidates that target Gram-positive bacteria for oral and/or parenteral treatment of infections caused by Clostridium difficile, Enterococcus, including vancomycin-resistant strains (VRE), Staphylococcus, including methicillin-resistant strains (MRSA), and Streptococcus, including antibiotic-resistant strains.

ACXP Intrinsic Value
Not Available
Back to Top